L
Leonard C. Glass
Researcher at Eli Lilly and Company
Publications - 25
Citations - 2854
Leonard C. Glass is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Insulin & Diabetes mellitus. The author has an hindex of 18, co-authored 25 publications receiving 2770 citations. Previous affiliations of Leonard C. Glass include University of Texas at San Antonio & University of Texas Health Science Center at San Antonio.
Papers
More filters
Journal ArticleDOI
Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
John B. Buse,Richard M. Bergenstal,Leonard C. Glass,Cory R. Heilmann,Michelle S. Lewis,Anita Y.M. Kwan,Byron J. Hoogwerf,Julio Rosenstock +7 more
TL;DR: Adding twice-daily exenatide injections improved glycemic control without increased hypoglycemia or weight gain in participants with uncontrolled type 2 diabetes who were receiving insulin glargine treatment.
Journal ArticleDOI
Improved Glycemic Control and Enhanced Insulin Sensitivity in Type 2 Diabetic Subjects Treated With Pioglitazone
Yoshinori Miyazaki,Archana Mahankali,Masafumi Matsuda,Leonard C. Glass,Srikanth Mahankali,Eleuterio Ferrannini,Kenneth Cusi,Lawrence J. Mandarino,Ralph A. DeFronzo +8 more
TL;DR: It is suggested that pioglitazone therapy in type 2 diabetic patients decreases lasting and postprandial plasma glucose levels by improving hepatic and peripheral (muscle) tissue sensitivity to insulin.
Journal ArticleDOI
Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
Mandeep Bajaj,Swangjit Suraamornkul,Paul K. Piper,Lou J. Hardies,Leonard C. Glass,Eugenio Cersosimo,Thongchai Pratipanawatr,Yoshinori Miyazaki,Ralph A. DeFronzo +8 more
TL;DR: The increase in plasma adiponectin concentration after thiazolidinedione therapy may play an important role in reversing the abnormality in hepatic fat mobilization and the hepatic/muscle insulin resistance in patients with type 2 diabetes.
Journal ArticleDOI
Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.
Mandeep Bajaj,Swangjit Suraamornkul,Thongchai Pratipanawatr,Lou J. Hardies,Wilailak Pratipanawatr,Leonard C. Glass,Eugenio Cersosimo,Yoshinori Miyazaki,Ralph A. DeFronzo +8 more
TL;DR: Improved splanchnic/peripheral glucose uptake and enhanced suppression of EGP contribute to the improvement in glycemic control in patients with type 2 diabetes.
Journal ArticleDOI
Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients
Y. Miyazaki,Leonard C. Glass,Curtis L Triplitt,Masafumi Matsuda,Kenneth Cusi,Archana Mahankali,Srikanth Mahankali,Lawrence J. Mandarino,Ralph A. DeFronzo +8 more
TL;DR: The results suggest that the beneficial effects of rosiglitazone on glycaemic control are mediated, in part, by the drug's effect on NEFA metabolism.